Forskning ved Københavns Universitet - Københavns Universitet

Forside

Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient

Publikation: Bidrag til tidsskriftTidsskriftartikel

Standard

Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient. / Nielsen, Karen Leth; Hansen, Katrine Hartung; Nielsen, Jesper Boye; Knudsen, Jenny Dahl; Schønning, Kristian; Frimodt-Møller, Niels; Hertz, Frederik Boëtius; Jansåker, Filip.

I: MicrobiologyOpen, Bind 8, Nr. 12, e941, 2019.

Publikation: Bidrag til tidsskriftTidsskriftartikel

Harvard

Nielsen, KL, Hansen, KH, Nielsen, JB, Knudsen, JD, Schønning, K, Frimodt-Møller, N, Hertz, FB & Jansåker, F 2019, 'Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient', MicrobiologyOpen, bind 8, nr. 12, e941. https://doi.org/10.1002/mbo3.941

APA

Nielsen, K. L., Hansen, K. H., Nielsen, J. B., Knudsen, J. D., Schønning, K., Frimodt-Møller, N., ... Jansåker, F. (2019). Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient. MicrobiologyOpen, 8(12), [e941]. https://doi.org/10.1002/mbo3.941

Vancouver

Nielsen KL, Hansen KH, Nielsen JB, Knudsen JD, Schønning K, Frimodt-Møller N o.a. Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient. MicrobiologyOpen. 2019;8(12). e941. https://doi.org/10.1002/mbo3.941

Author

Nielsen, Karen Leth ; Hansen, Katrine Hartung ; Nielsen, Jesper Boye ; Knudsen, Jenny Dahl ; Schønning, Kristian ; Frimodt-Møller, Niels ; Hertz, Frederik Boëtius ; Jansåker, Filip. / Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient. I: MicrobiologyOpen. 2019 ; Bind 8, Nr. 12.

Bibtex

@article{318b7e3a7eea47fb876957ff260888bf,
title = "Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient",
abstract = "Pivmecillinam (amdinocillin pivoxil) is the recommended first-choice antibiotic used to treat urinary tract infections (UTIs) in Denmark. The frequency of mutation to mecillinam (MEC) resistance is described as high in vitro; however, treatment of UTI has a good clinical response and prevalence of mecillinam resistance in Escherichia coli remains low despite many years of use. We describe occurrence of in vivo mecillinam resistance in a clinical isolate of ESBL-producing E. coli following pivmecillinam treatment. The identified phenotypic differences in the mecillinam resistant isolate compared with the original mecillinam susceptible isolate were a full-length LPS with O-antigen (O25), mecillinam resistance and a lower MIC for ceftazidime. Regarding genotype, the resistant isolate differed with a mutation in blaCTX-M-15 to blaCTX-M-127 , loss of a part of a plasmid and a genomic island, respectively, and insertion of a transposase in wbbL, causing the rough phenotype. The observed mecillinam resistance is expected to be caused by the mutation in blaCTX-M-15 with additional contribute from the serotype shift. We continue to recommend the use of pivmecillinam as first-line treatment for UTI.",
author = "Nielsen, {Karen Leth} and Hansen, {Katrine Hartung} and Nielsen, {Jesper Boye} and Knudsen, {Jenny Dahl} and Kristian Sch{\o}nning and Niels Frimodt-M{\o}ller and Hertz, {Frederik Bo{\"e}tius} and Filip Jans{\aa}ker",
year = "2019",
doi = "10.1002/mbo3.941",
language = "English",
volume = "8",
journal = "MicrobiologyOpen",
issn = "2045-8827",
publisher = "JohnWiley & Sons Ltd",
number = "12",

}

RIS

TY - JOUR

T1 - Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient

AU - Nielsen, Karen Leth

AU - Hansen, Katrine Hartung

AU - Nielsen, Jesper Boye

AU - Knudsen, Jenny Dahl

AU - Schønning, Kristian

AU - Frimodt-Møller, Niels

AU - Hertz, Frederik Boëtius

AU - Jansåker, Filip

PY - 2019

Y1 - 2019

N2 - Pivmecillinam (amdinocillin pivoxil) is the recommended first-choice antibiotic used to treat urinary tract infections (UTIs) in Denmark. The frequency of mutation to mecillinam (MEC) resistance is described as high in vitro; however, treatment of UTI has a good clinical response and prevalence of mecillinam resistance in Escherichia coli remains low despite many years of use. We describe occurrence of in vivo mecillinam resistance in a clinical isolate of ESBL-producing E. coli following pivmecillinam treatment. The identified phenotypic differences in the mecillinam resistant isolate compared with the original mecillinam susceptible isolate were a full-length LPS with O-antigen (O25), mecillinam resistance and a lower MIC for ceftazidime. Regarding genotype, the resistant isolate differed with a mutation in blaCTX-M-15 to blaCTX-M-127 , loss of a part of a plasmid and a genomic island, respectively, and insertion of a transposase in wbbL, causing the rough phenotype. The observed mecillinam resistance is expected to be caused by the mutation in blaCTX-M-15 with additional contribute from the serotype shift. We continue to recommend the use of pivmecillinam as first-line treatment for UTI.

AB - Pivmecillinam (amdinocillin pivoxil) is the recommended first-choice antibiotic used to treat urinary tract infections (UTIs) in Denmark. The frequency of mutation to mecillinam (MEC) resistance is described as high in vitro; however, treatment of UTI has a good clinical response and prevalence of mecillinam resistance in Escherichia coli remains low despite many years of use. We describe occurrence of in vivo mecillinam resistance in a clinical isolate of ESBL-producing E. coli following pivmecillinam treatment. The identified phenotypic differences in the mecillinam resistant isolate compared with the original mecillinam susceptible isolate were a full-length LPS with O-antigen (O25), mecillinam resistance and a lower MIC for ceftazidime. Regarding genotype, the resistant isolate differed with a mutation in blaCTX-M-15 to blaCTX-M-127 , loss of a part of a plasmid and a genomic island, respectively, and insertion of a transposase in wbbL, causing the rough phenotype. The observed mecillinam resistance is expected to be caused by the mutation in blaCTX-M-15 with additional contribute from the serotype shift. We continue to recommend the use of pivmecillinam as first-line treatment for UTI.

U2 - 10.1002/mbo3.941

DO - 10.1002/mbo3.941

M3 - Journal article

C2 - 31573735

VL - 8

JO - MicrobiologyOpen

JF - MicrobiologyOpen

SN - 2045-8827

IS - 12

M1 - e941

ER -

ID: 231595544